

Financial Tear Sheet

Corporate Profile

Tactile Medical is a leader in treatment options for lymphedema and venous ulcer therapies. Tactile Medical develops advanced home therapy devices to improve health and quality of life for patients with chronic swelling conditions.

Headquartered in Minneapolis, Minnesota, we advocate for patient access and serve tens of thousands of patients through a national network of product specialists and trainers, reimbursement experts, patient advocates, and clinical staff. Our products are proven to improve quality of life, increase clinical efficacy, and reduce overall healthcare costs.

Primary IR Contact

Mike Piccinino, CFA
 Westwicke Partners on behalf of
 Tactile Medical
Phone: +1 443-213-0500
E-mail:
InvestorRelations@tactilemedical.com

Stock Information

TCMD (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$30.29
Change (%)	▼ 0.1 (0.33%)
Volume	86,164
52 Week Low	\$10.00
Market Cap	\$514,810,855
Rolling EPS	0.07
PE Ratio	443.714
Shares Outstanding	16,940,140
Data as of July 26, 2017 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News & Upcoming Events

July 11, 2017 - 4:06 p.m.

Tactile Medical Appoints Dr. Thomas F. O'Donnell, Jr. as Chief Medical Officer

July 6, 2017 - 11:30 a.m.

Tactile Medical to Release Second Quarter 2017 Financial Results on August 7, 2017

June 1, 2017 - 8:31 a.m.

Tactile Medical Receives FDA 510(k) Clearance for Flexitouch® Plus, with Improved Therapy for At-Home Lymphedema Treatment

Date

Title

August 7,
2017 5:00
p.m. ET

**Q2 2017 Tactile Systems Technology,
Inc. Earnings Conference Call**

SEC Filings

Filing Date

Form

July 24, 2017

4

July 14, 2017

4

July 6, 2017

4

July 6, 2017

4
